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ABSTRACT

Skyler Crane: Crystallization Efforts for an Engineered Nickel-Binding Protein, Gold-Bovine
Serum Albumin Nanoclusters, and an Artificial Hydrogenase Mimic

(Under the direction of Dr. Saumen Chakraborty)

Protein crystallization is fundamental to modern research efforts given its ability to
determine a protein’s structure as well as the interactions that structure allows and relies upon.
This process, though lacking direct application, provides necessary information for subsequent
research efforts for which applications may be explored. As such, efforts were taken to crystallize
nickel-binding protein (NBP) reengineered from Copper Storage Protein 1 (Csp1) in its apo and
metal bound form, Bovine Serum Albumin (BSA) in its apo and gold bound form (Au-BSA), and
an artificial de novo tetramer hydrogenase mimic peptide to better inform future research actions
for these respective molecules. Efforts yielded apo-NBP crystals of sufficient quality from which
a structure could be determined. Apo-BSA crystals were formed; however, their morphology was
unsuitable for structure determination. Au-BSA, Ni-NBP, and the de novo tetramer currently are
undergoing condition optimization to more efficiently develop crystals for structure elucidation.
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Chapter 1: Introduction

1.1 Bragg’s Law
Max von Lane’s initial use of x-rays on crystal structures in 1912 gradually metamorphosized
into the modern science of crystallography.1 Crystallography is used to deduce the structure of a
material of interest as it is in a solid, crystalline form by studying the patterns formed when incident
x-rays diffract off of atoms in a material and interact with other diffracted x-rays.2 This process
assists in the elucidation of the relationship between that material’s properties and structure. As
such, crystallography is used for tasks ranging from soil analysis3 to small molecule imaging.4,5
An application of this method relevant to protein structure elucidation was John Kendrew and Max
Perutz’s determination of myoglobin’s structure,6 an act that saw the duo awarded the 1962 Nobel
prize in chemistry and catalyzed subsequent protein crystallization efforts.
To expand on previous statements, crystallography uses the angles and intensities resulting
from the interactions of diffracted x-rays to determine electron density inside the crystal which can
then be used to determine atomic bond lengths and angles. This is feasible via the following
observation: When x-rays enter a crystal, they scatter off of the sample’s atoms to interfere with
other scattered x-rays similar to how a shore wall breach causes waves to knock against one
another.7 This phenomenon was later algebraically expressed as Bragg’s Law provided in Eq. 1
and visually simulated in Figure 1.
𝑛𝜆 = 2𝑑 sin 𝜃……. Eq. 1
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Figure 1: A diagram depicting a lattice adhering to Bragg’s Law.8

Bragg’s Law’s variables are defined as follows: n = a whole number of wavelengths along path
CBD as shown in Figure 2 (i.e. order of reflection), λ = the incident ray’s wavelength, d = the
distance between the crystal’s lattice planes, and θ = the angle of reflection.2 Bragg’s Law is
applicable to instances of constructive interference and elastic light scattering. Deviations from
these conditions results in its mathematic expression being rendered irrelevant. For instance, if n
were a fraction, the corresponding θ value would cause destructive interference with the reflected
wavelength thus destroying it and rendering a diffraction pattern unobservable.
1.2 Generalized Crystallization Procedure(s)
This information, though useful, does not describe how to create a crystal for which this
phenomenon can be applied. Considering this work’s focus, subsequent discussion of
crystallization will correlate most closely with proteins and protein-metal complexes. A general
outline for protein crystallization is detailed here. The pure protein is either commercially acquired
or prepared via transforming the gene that codes the desired protein into a bacterium, stimulating
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that gene’s expression, then purifying that desired protein from the resulting supernatant following
centrifugation of the bacterial cultural. From there, a variety of conditions are tested (“screened”)
to optimize the system’s (i.e. mother liquor’s) components. The conditions deemed most promising
are then further optimized via trial and error to create parameters that result in the most welldeveloped crystals. The crystals are then extracted from the mother liquor and exposed to x-ray
diffraction techniques so the protein’s structure can be determined by software analysis. This
process is visualized in Figure 2.

Figure 2: Visualization of general crystallization procedure. Note the structure presented here is not from this study
and is there for demonstrative purposes

Additionally, it is necessary to address the fundamentals involved with protein crystal
formation. Any crystal morphology descriptors are mimicked from professional practice.9 Crystal
formation is divided into two distinct steps: nucleation and growth. Nucleation is the transition of
protein molecules into an ordered state known as a critical nucleus from an unordered state, and
growth is the expansion of the critical nucleus via “dislocation growth” and “growth by twodimensional nucleation” phenomena10,11 which is thought to result from statistical fluctuations in
12

a solution’s properties.1,12,13,14 What is known, however, is crystal formation requires a
supersaturated environment. This observation is visualized in Figure 3.

Figure 3: A generic phase diagram detailing conditions for crystallization. Borders between subareas indicate a state
of equilibrium in the mother liquor

As can be seen in Figure 3, the more ideal crystal morphologies are more likely to form in
supersaturated conditions with examples being the sharp-angled single crystals seen in the figure’s
Metastable region and the quasi crystals, perhaps microcrystals, shown in the Labile region. If the
protein and salt concentrations are too high, precipitation occurs preventing crystal formation, and
not including enough protein or salt results in an uneventful solution. As can also be noted in
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Figure 3, the range for supersaturation is broad and therefore differs depending on the crystal
species further reinforcing the importance of mother liquor condition optimization.
Protein crystallography methods must consider the nature of proteins, namely that they
largely coevolved in living systems based on aqueous chemistry bounded by specific pH and
temperature parameters from which deviation equates to destruction.1,12 Additionally, protein
crystals typically are more fragile than crystals of other molecule types due to their large size and
complexity exasperating the consequences of conformational dynamics (i.e. polymorphism) based
on Anfinsen’s dogma.4 They also diffract x-rays poorly due to relatively low degrees of internal
order and the existence of solvent regions1 and are damaged by extended exposure to
electromagnetic radiation.1 Therefore, even when the mother liquor’s conditions are appropriate
for a protein, protein crystals tend to develop to different degrees even when said conditions are
replicated rendering their structures indecipherable by software such as CCP4, Phenix, and
Molrep. Thus, this phenomenon requires even more numerous replications of the same condition
to determine with increased certainty that condition’s viability. This can be accomplished in many
ways, but this discussion will be limited to two methods due to their relevance to this work:
hanging drop vapor diffusion and sitting drop vapor diffusion. Schematics for each method are
provided in Figure 415 and Figure 515 respectively.
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Figure 4: Diagram of the hanging drop method where the reservoir solution (blue) typically is composed of
precipitant and buffer, and the protein solution (red) contains the same components in lower concentrations as well
as trace metals or ions necessary for precipitation.

Figure 5: Diagram of the sitting drop method where conditions are identical to the hanging drop method except the
protein drop sits on a dais above the reservoir solution instead of hanging from the coverslip.

Both methods depicted above use the same principles and differ only by the orientation of the drop.
An aqueous solution of protein, buffer, and precipitate and a reservoir solution made of the same
components minus the protein is created and isolated as a closed system by high-vacuum grease.
Within this closed system, the reservoir solution contains a higher concentration of precipitate than
the protein solution causing an imbalance in water distribution which is solved by diffusion of
water into the reservoir solution to restore the system’s equilibrium. This results in the protein
solution’s protein concentration gradually increasing thereby increasing the probability of
crystallization. These systems test for a single set of conditions which can then be replicated as
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needed. Typically, these systems are confined to “wells” in a tray-like apparatus alongside other
systems to allow for more effective condition screening. One “tray” configuration that is used in
this work is shown in Figure 6.

Figure 6: One of the trays used in this work. It is composed of a plastic 6 x 4 well system with a plastic cover. Note
that the plastic cover is not the coverslip for the wells but it rather a protective shell to isolate the glass coverslips
from damage.
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This work applied these methods and their associated variable manipulations to
crystallization efforts of apo-nickel binding protein (apo-NBP), its nickel-bound form (Ni-NBP),
apo-bovine serum albumin (apo-BSA), its gold-bound form (Au-BSA), and an artificiallysynthesized de novo tetramer hydrogenase mimic. Additional efforts were made to also purify
nitrobindin heme protein (NBHP).
1.3 Nanoclusters
Considering the formation of metal-protein complexes, discussion of nanoclusters is
required to frame this work’s results. Nanoclusters are defined as submicroscopic particles ranging
in size from less than one nanometer to two-point-two nanometers (Figure 7).16

Figure 7: Visualization of nanocluster size alongside other submicroscopic particle categories for scale.

Nanoclusters have unique properties compared to larger nanoparticles leading scientists to
speculate that these complexes have applications as energy production catalysts and biological
labeling/sensing agents -- characteristics shared by gold nanoclusters.17,18
The work enclosed is basic scientific research with no direct applications; however, its
conductance provides greater insight into the relationships between NBP’s, NBHP’s, BSA’s, and
THE DE NOVO TETRAMER’S’s respective structures, properties, and inter/intramolecular
interactions. This, in turn, allows for more thorough investigations into potential applications for
17

the molecules listed. In short, this work is an intermediary - a bridge of sorts - needed to direct
future research efforts.
Chapter 2: NBP

2.1 NBP Background
NBP is an artificial hydrogenase mimic reengineered from Copper storage protein 1 (Csp1)
derived from bacteria Methylosinus trichosporium OB3b (PDB 5FJE).19,20 NBP’s tetramer
structure differs from Csp1’s by fifteen mutations: Nine cysteine [Cys] residues were mutated to
seven alanine [Ala], one leucine [Leu], and one valine [Val] residues respectively; and six histidine
[His] residues were modified into three glutamine [Gln] and three asparagine [Asn] residues. The
Ala residues’ purpose was to retain the protein’s compact helical structure given its similar size to
the replaced Cys residues (Cys33, Cys37, Cys51, Cys90, Cys106, Cys110, and Cys117), and the
purpose of the Leu and Val residues (previously Cys103 and Cys94 respectively) was to provide
hydrophobic packing to ensure the protein remained well-folded. As for the Gln and Asn residues,
their purpose was to prevent Ni-binding competition by being noncoordinating whilst retaining the
previous residues’ polarity. Csp1’s gene sequence is provided in Figure 8, its corresponding amino
acid sequence is provided in Figure 9, and the gene and residue sequence modifications conducted
for NBP’s creation are provided in Figure 10 and Figure 11 respectively. Figure 12 provide 3D
models for Csp1 and NBP.
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CATATG
TGGAGCCACCCGCAGTTCGAGAAGGGTGGCAGCGGTGAAGACCCGCACGCGGGCCA
CAAAATGAGCCACGGTGCGAAGTACAAAGCGCTGCTGGACAGCAGCAGCCACTGCG
TGGCGGTTGGTGAAGATTGCCTGCGTCACTGCTTTGAAATGCTGGCGATGAACGACG
CGAGCATGGGTGCGTGCACCAAGGCGACCTATGATCTGGTGGCGGCGTGCGGTGCG
CTGGCGAAACTGGCGGGTACCAACAGCGCGTTCACCCCGGCGTTTGCGAAGGTGGT
TGCGGACGTTTGCGCGGCGTGCAAGAAAGAGTGCGATAAGTTCCCGAGCATCGCGG
AGTGCAAAGCGTGCGGTGAAGCGTGCCAAGCGTGCGCGGAGGAATGCCACAAAGTG
GCGGCGTAA
CCATGG
Figure 8: The gene sequence for Csp1 is labeled in uncolored script. Restriction sites Ndel and Ncol are labeled in
cyan and gray respectively. The stop codon is labeled in red.

WSHPQFEKGGSGEDPHAGHKMSHGAKYKALLDSSSHCVAVGEDCLRHCFEMLAMND
ASMGACTKATYDLVAACGALAKLAGTNSAFTPAFAKVVADVCAACKKECDKFPSIAE
CKACGEACQACAEECHKVAA
Figure 9: The primary sequence for Csp1 is labeled in uncolored script. The Strep Tag residues in yellow renders
affinity chromatography capable of purifying NBP. A spacer sequence is labeled in violet. Cys residues are printed in
red.

CATATG
TGGAGCCATCCGCAGTTTGAGAAGGGTGGTAGCGGTGAAGATCCGAACGCGGGTCA
GAAAATGAGCCAAGGTGCGAAATACAAGGCGCTGCTGGACAGCAGCAGCCAGTGC
GTGGCGGTTGGCGAGGATGCGCTGCGTAACGCGTTCGAAATGCTGGCGATGAACGA
TGCGAGCATGGGCGCGGCGACCAAAGCGACCTACGATCTGGTGGCGGCGTGCGGTG
CGCTGGCGAAACTGGCGGGTACCAACAGCGCGTTCACCCCGGCGTTTGCGAAAGTG
GTTGCGGATGTGTGCGCGGCGGCGAAGAAAGAGGTTGATAAATTTCCGAGCATCGC
GGAACTGAAAGCGGCGGGCGAAGCGGCGCAGGCGTGCGCGGAAGAAGCGAATAAA
GTGGCGGCGTAA
CCATGG
Figure 10: The gene sequence for NBP is labeled in uncolored script. Restriction sites Ndel and Ncol are labeled in
cyan and gray respectively. The stop codon is labeled in red.

WSHPQFEKGGSGEDPNAGQKMSQGAKYKALLDSSSQCVAVGEDALRNAFEMLAMND
ASMGAATKATYDLVAACGALAKLAGTNSAFTPAFAKVVADVCAAAKKEVDKFPSIAE
LKAAGEAAQACAEEANKVAA
Figure 11: The primary sequence for NBP is labeled in uncolored script. The Strep Tag residues in yellow renders
affinity chromatography capable of purifying NBP. A spacer sequence is labeled in violet. Cys residues forming the
Ni-binding site are highlighted in red. Residues modified from His are labeled in orange, and residues modified from
Cys are labeled in white.
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Figure 12: 3D models for Csp1 (right) and NBP (left). Models were created in NAMD using CHARMM22 force
fields.

The remaining four Cys residues [Cys26, Cys62, Cys87, and Cys113] in Figure 11 were retained
so each α-helix had one Cys residue to form NBP’s Ni-binding site. This binding site is visible in
Figure 13.

Figure 13: NBP’s nickel binding site. Model was created using CHARM22 force fields

Additionally, a variant of NBP with no Cys residues was also created to ensure the absence of
nickel binding. The Cys positions and residue mutations for this variant were as follows:
Cys26→Ala, Cys62→Val, Cys87→Ala, and Cys113→Val.
20

2.2 NBP Expression and Purification Procedure
The procedure for NBP expression was as follows: A synthetic NBP gene with a Nterminal Strep-tag and GGS spacer (Genscript) was cloned into a pET 29a (+) vector at its
NdeI/NcoI restriction sites. The gene was dissolved at 100 ng/μL in Milli-Q water and stored at
−20°C. 50 μL of E.cloni EXPRESS DUOs BL21(DE3) chemically competent cells (Lucigen) was
added to 1 μL of NBP gene in a 10 mL culture tube and incubated on ice for 30 minutes. The cells
were then subjected to heat shock at 42°C for 45 seconds and further incubated in ice for 10
minutes. Cells were recovered with 1 mL of LB media in an incubator-shaker (Thermo Fisher
MAXQ 4000) at 37°C for 1 hour. 50 μL of the cells were then plated on kanamycin LB agar plates
(Figure 14) and incubated overnight at 37°C.

Figure 14: Representative LB Agar plate used for protein expression

10 mL primary cultures in LB media supplemented by 50 mg/mL kanamycin (Fisher) were
inoculated with single colonies and grown overnight at 180 rpm at 37°C using the same incubatorshaker as previously described. 1 L of secondary culture in LB media supplemented by kanamycin
was inoculated with 10 mL of primary culture and grown for 3-4 hours at 180 rpm at 37°C until
21

an optical density at 600 nm (OD600) reached approximately 0.55. The cultures were then induced
with 1 mM (final concentration) of isopropyl β-D-1-thiogalactopyranoside (IPTG; Goldbio). The
induced culture was then allowed to grow for six hours at 180 rpm at 30°C. 10 mL of uninduced
culture was grown, pelleted, and sonicated under conditions similar to those of the induced culture
and then checked as a control on the gel. The cells were harvested at 6000 rpm (SORVALL RC
5B PLUS; Figure 15) for 10 minutes, and the pellets were stored in −20°C overnight.

Figure 15: Picture representative of cells harvested at 6000 rpm

The following day, the pellets were resuspended in 50 mL of lysis buffer consisting of 20
mM tris(hydroxymethyl)aminomethane (Tris-HCl; VWR) pH 8.5, 1 mM dithiothreitol (DTT;
VWR), 1 mM phenylmethane sulfonyl fluoride (PMSF; Biosynth Inc.), 1 mM EDTA, and 10
μg/mL deoxyribonuclease (DNase I; Worthington Biochemical Corp.) followed by sonication on
ice (Branson) for 3 minutes using a 10/20 second on/off cycle at 10% amplitude. The lysate
(Figure 16) was then centrifuged in an SS-34 rotor (Thermo Fisher SORVALL RC6+ Centrifuge)
at 14,000 rpm for 45 minutes at 4°C.
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Figure 16: Representative centrifugation tubes used to contain lysate. Note the supernatant has been removed.
The supernatant was then filtered through a 0.45 μm filter and used for purification using
a Strep-Tactin affinity column (GE Healthcare; Figure 17) pre-equilibrated with wash buffer (100
mM Tris, 150 mM NaCl, 1 mM EDTA, pH 8.0). The supernatant was loaded onto a 5 mL column
at a flowrate of 4 mL/min using an Econo gradient pump (Bio-Rad; Figure 17) followed by
washing with 20 mL of wash buffer to remove unbound proteins. The protein was eluted using 20
mL of elution buffer consisting of 100 mM pH 8.0 Tris-HCl, 150 mM NaCl, 1 mM EDTA, and
2.5 mM D-desthiobiotin (Sigma-Aldrich). The columns were regenerated using 10 mL of Milli-Q
water followed by 16 mL of 0.5 M NaOH. The columns were then washed with 20 mL of Milli-Q
water to remove the NaOH. Once the pH became neutral, the columns were stored back in the
wash buffer.
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Figure 17: Strep-Trap affinity column (left) and the Econo gradient pump (right) used and associated setup

Following affinity column purification, the protein was further purified by size exclusion
chromatography (SEC). The protein was concentrated to 2 mL using 10 kDa MWCO filters
(Millipore) centrifuged at 4000 rpm (Thermo Fisher Heraeus Megafuge 16R) and then filtered
using a 0.22 μM filter (VWR). 1 mM (tris(2-carboxyethyl)phosphine) (TCEP; Goldbio) was added
to the protein and loaded into an SEC column (GE Healthcare XK 16 High Load 16/60, Superdex
75, prep grade; Figure 18) with a 2 mL injection loop.

Figure 18: Size exclusion chromatography column used and associated setup
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The purification was performed on an AKTA purifier 10 using elution buffer (50 mM Tris, 150
mM NaCl, pH 7.8) at a flow rate of 1 mL/min. The fraction corresponding to the protein peak
(56−63 mL elution volume; Figure 19) was taken, and its concentration was determined using Ɛ280
= 8480 M-1cm-1 and the Beer-Lambert Law (Eq. 2) where all variables correspond to values
obtained at λ280. A = absorbance, Ɛ = molar extinction coefficient, c = concentration, and l =
instrument pathlength.

Figure 19: a) Size exclusion chromatogram of NBP purification showing the major peak corresponding to pure NBP
with elution volume 56-63 mL. b) MALDI-MS of apo-NBP showing the correct identity of the protein (molecular ion
peak observed at 13520 Da; calculated 13519 Da). The +224 Da peak marked with * is a non-specific adduct of the
protein with sinapinic acid matrix.

𝐴 = Ɛ𝑐𝑙………. Eq. 2
NBP’s purification cycle takes 5 days. The Cys-free variant of NBP was expressed and purified
to homogeneity using the same procedure as NBP’s with a yield of approximately 13 mg/L of
bacterial culture. The Cys-free protein’s purity and mass were verified by SDS-PAGE and MALDI
MS (observed 13,516 Da; calculated 13,518 Da), respectively as is seen in Figure 20a and Figure
20b.
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Figure 20: SDS-PAGE (a) and MALDI-MS (b) the Cys-free variant of NBP. The MALDI (observed 13516 Da; calc.
13518 Da) data was collected using sinapinic acid matrix.

2.3 Apo-NBP Crystallization
All crystallization occurred at ~20°C. First, a Pre-Crystallization Test (PCT) was
performed to optimize the quantity of protein required for crystallization. Reagents were made to
match those available in Hampton Research’s HR2-140 commercial kit.21 A protein concentration
of 28 mg/mL was deemed most efficient from observations of PCT results. Following this, the
sparse matrix reagent kits Crystal Screen 1 (HR2-110) and Crystal Screen 2 (HR2-112) (Hampton
Research)22 were used to determine crystallization conditions. Out of 98 condition sets tested, only
one set yielded a crystal (Figure 21a) after one year of growth with the following conditions: 0.2
M ammonium sulfate, 0.1 M sodium acetate trihydrate (pH 4.6), 25% w/v polyethylene glycol
(PEG) 4,000. This crystal, and all others in this work, were viewed by an Olympus SZH light
microscope.
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Figure 21: (a) apo-NBP crystal caught in an extraction loop. The red gridlines indicate the area used for x-ray
diffraction. (b) apo-NBP crystals acquired via Bis-Tris screen tray

Additionally, considering the time required for the above crystallization to be successful,
investigation into other viable condition sets was conducted. Based on successful crystallization
attempts of apo-NBP’s precursor apo-Csp1 in the literature,23 similar screen conditions were
established for apo-NBP. Of these conditions, the following screen offered the most developed
results: 0.1 M Bis-Tris, PEG 3350 (22-27%), and pH (6.3-6.6). Final well volumes were 1 mL. All
drops were created with a ratio of 1:1 protein solution to well solution. The protein concentration
used was 25 mg/mL. This screen is simulated in Figure 22.

Figure 22: A simulated view of tray conditions for apo-NBP crystallization. Each rectangle corresponds to a single
well that possesses characteristics of the corresponding PEG and pH row and column respectively. Conditions where
crystals developed are marked by an “X”
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Both hanging and sitting drop models were capable of forming crystals under the same screen
conditions. Some of the better developed crystals from this screen are provided in Figure 21b.
X-ray diffraction occurred at the Brookhaven National Lab’s National Synchrotron Light
Source II (NSLS-II) via the Frontier Microfocusing Macromolecular Crystallography (FMX)
beamline. The diffraction pattern observed from the above crystals is shown in Figure 23.

Figure 23: The diffraction pattern for apo-NBP crystals observed. The intense, luminous dots of lights within the
yellow oval correspond to relevant diffracted x-rays

A resolution of 2.8-3.0 Å was observed from collected data, and a structure for apo-NBP was
created (Figure 23).

Figure 24: apo-NBP structure determined via data collected from x-ray diffraction of crystals retrieved from
commercial crystal screen and Bis-Tris trays. Note the red arrow indicating the empty nickel binding site

28

The nickel binding site characteristic of the protein is visible as is its tetramer structure and αhelices. The model provided in Figure 24 confirmed the successful redesign of Csp1 into NBP
and the crystallization of its apo form.
2.4 Ni-NBP Crystallization
As of now, efforts to crystallize nickel-bound NBP (Ni-NBP) are directed toward condition
optimization. Crystallization attempts have been made at both ~4°C and ~20°C. Guided by the
success of crystallizing apo-NBP from conditions used for its protein pre-cursor, the literature was
referenced again to determine appropriate conditions for Ni-NBP.23 The conditions under
optimization currently are as follows: 0.03 M MgCl2, 0.03 M CaCl2, 0.1 M Tris-Bicine pH 8.5,
12.5% v/v 2-methyl-2,4 pentanediol (racemic) plus 12.5% PEG 1000 and 12.5% PEG 3350. As
with the apo-NBP screen trays, the pH and respective PEG concentrations are being varied.
Optimization efforts include varying pH values from 8.0-8.7 at increments of 0.1, and the PEG
concentrations from 11.5-16.5% at increments of 1.0%. The final well volume is 1 mL, and the
drop ratio of protein solution to mother liquor is 1:1. Two equivalents of nickel are currently being
introduced to the protein solutions. The protein concentrations under optimizations were 25
mg/mL and 28 mg/mL. These conditions are tabulated in screen format in Figure 25.
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Figure 25: Conditions under optimization for Ni-NBP in screen format

If Ni-NBP crystals were to form for these conditions, they would be harvested and sent to
Argonne National Laboratory for characterization.
Chapter 3: NBHP
3.1 NBHP Background
NBHP had different expression and purification procedures compared to NBP due to
structural differences. NBHP, also known as Arabidopsis thaliana nitrobindin (At-Nb), possesses
a β-barrel composed of ten antiparallel residue strands and is capable of binding nitric oxide
(NO).24,25 Due to identification of structural homologs of NBHP in Mycobacterium tuberculosis,
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it is believed a novel family of NBHPs has potential to represent all β-barrel heme-binding
proteins.26 Visualizations relevant to NBHP are provided in Figure 26.

Figure 26: From left to right, models for NBHP’s heme environment, central electrostatic network, and N-terminal
electrostatic network are provided. Electrostatic interactions within a distance threshold of 3.5 Å are represented by
continuous lines. The models were created with the UCSF-Chimera package27

3.2 NBHP Expression and Purification Procedure
The procedure for NBHP protein expression was as follows: A synthetic gene for
Nitrobindin containing a N-terminal Strep-tag (WSHPQFEK) and a GGS spacer (Genscript) was
cloned into a pET 29a (+) vector at the NdeI/NcoI restriction sites. The gene was dissolved at 100
ng/µL in Milli-Q water and stored at -20°C. In a pre-cooled 10 mL culture tube, 1 µL of gene and
50 µL of E.cloni EXPRESS DUOs BL21(DE3) chemically competent cells (Lucigen) were added
and incubated in ice for 30 minutes. The cells were then subjected to heat shock at 42°C for 45
seconds and further incubated in ice for 10 minutes. Cell recovery was performed with 1 mL of
LB media in an incubator-shaker (ThermoFisher MAXQ 4000) at 37°C for 1 hour. 50 µL of the
cells were then plated on kanamycin LB agar plates and incubated at 37°C overnight. A 10 mL
primary culture was inoculated with a freshly grown colony in LB media supplemented with 50
mg/mL kanamycin (Fisher) and was grown overnight at 180 rpm at 37°C. 1 L of kanamycinsupplemented secondary culture in LB media was inoculated with 10 mL of primary culture and
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grown for 3-4 hours at 180 rpm at 37°C until the OD600 reached approximately 0.55. The culture
was then induced with 0.5 mM (final concentration) of isopropyl β-D-1-thiogalactopyranoside
(IPTG; Goldbio) and allowed to grow for 24 hours at 160 rpm at 30°C. The induced cells were
harvested at 6000 rpm (SORVALL RC 5B PLUS) for 10 minutes and the pellets were stored
overnight at -20°C.
The following day, the pellets were resuspended in 50 mL of lysis buffer comprised of 20
mM tris(hydroxymethyl)aminomethane (Tris-HCl; VWR) pH 8.5, 1 mM dithiothreitol (DTT;
VWR), 1mM phenylmethane sulfonyl fluoride (PMSF; Biosynth Inc.), 1 mM EDTA, and 4 µL
deoxyribonuclease (DNase I; ThermoFischer scientific.) followed by sonication on ice (Branson)
for 3 minutes using a 10/20 second on/off cycle at 10% amplitude. The lysate was then centrifuged
in an SS-34 rotor (Thermo Fisher SORVALL RC6+ Centrifuge) at 14,000 rpm for 45 minutes at
4°C. The supernatant was filtered through a 0.45 µm filter and purified by a Strep-Tactin affinity
column (GE Healthcare) pre-equilibrated with wash buffer (100 mM Tris, 150 mM NaCl, 1 mM
EDTA, pH 8.0). The supernatant was loaded onto a 5 mL column at a flowrate of 4 mL/min using
an Econo gradient pump (Bio-Rad) followed by washing with 25 mL of wash buffer. The protein
was eluted using 8 mL of elution buffer (2.5 mM [final concentration] D-desthiobiotin in wash
buffer; Sigma Aldrich). The column was regenerated by washing it with 25 mL of water followed
by 15 mL of 0.5 M NaOH. The column was then washed with water until the pH became neutral
at which point it was stored back in the wash buffer.
Regarding heme extraction, the purified NBHP was then exchanged in cold water using a
PD10 column prior to diluting the protein to 25 μM. 2M HCl was added to the resulting solution
so its concentration was 1% followed by addition of equal volume of methyl ethyl ketone (MEK).
NBHP was left undisturbed for 10 minutes before the heme layer was extracted via glass pipette.
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Two additional washes with MEK were conducted to ensure complete heme extraction. NBHP
was then dialyzed in water overnight to discard excess MEK.
Following dialyzation, heme repacking was performed at 4°C. NBHP was diluted to 10
μM using 20 mM Tris buffer, and 10 mM heme stock was prepared in 66 mM NaOH. Repacking
was done by adding 0.5 equivalents of heme to the NBHP solution whilst stirring 10 minutes per
each half equivalent added until 2 equivalents of heme had been added. The protein was left to stir
for about 2-3 hours after the final addition of heme to allow for complete repacking.
NBHP’s induction efficiency and purity were checked using a 12% Tris-Tricine SDSPAGE gel. 5 µL of loading dye was added to 20 µL of each sample and heated at 90°C for 10
minutes. 15 µL of each analyte was then loaded onto the gel against a high molecular weight
protein ladder and run at 100 V for 3 hours in a water circulated electrophoresis chamber (Thermo
Fisher). The resulting gel (Figure 27) was stained in 0.3% coomassie blue solution composed of
45% methanol, 10% glacial acetic acid, 45% H2O. The gel was destained in a solution composed
of 30% methanol, 10% glacial acetic acid, and 60% H2O.

Figure 27: SDS-Page gel consisting of three (3) lanes. From the left, these lanes corresponded to the protein ladder,
induced protein control, and purified protein
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Chapter 4: BSA
4.1 Background
Bovine serum albumin (BSA) is a ~66463 kDa globular protein found in cows. Apo-BSA
has been successfully crystallized28,29 and had its structure modeled (Figure 28), but structure
when bound to gold have not been reported.

Figure 28: Literature structures of BSA from different studies. PDB codes for each structure are (a) = 3V03 and (b)
= 4F5S. Resolution for (a) and (b) were 2.7 Å and 2.47 Å respectively.

Despite it already being crystallized, attempts to crystallize apo-BSA were made in this work to
check reproducibility of the methods described in the literature.
4.2 Purification Procedure
The protocol for BSA purification was similar to NBP’s SEC purification step. BSA
(VWR) was dissolved in 50 mM Tris, 150 mM NaCl, pH 7.8 buffer then concentrated protein to
2 mL using 10 kDa MWCO filters (Millipore) centrifuged at 4000 rpm (Thermo Fisher Heraeus
Megafuge 16R). The resulting solution was then sieved through a 0.22 μM filter (VWR). 1 mM
tris(2-carboxyethyl)phosphine (TCEP; Goldbio) was added to the protein and loaded into an SEC
column (GE Healthcare XK 16 High Load 16/60, Superdex 75, prep grade; Figure 18) with a 2
mL injection loop. The purification was performed on an AKTA purifier 10 using elution buffer
(50 mM Tris, 150 mM NaCl, pH 7.8) at a flow rate of 1 mL/min. The fraction corresponding to
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the protein peak (56−63 mL elution volume) was taken, and its concentration was determined
using Ɛ280 = 43824 M-1cm-1 and the Beer-Lambert Law (Eq. 2). The purified protein was stored at
−80°C.
4.3 Apo-BSA Crystallization
Current efforts to crystallize apo-BSA are directed toward condition optimization. All
crystallization occurred at room temperature (~20°C). Guided by success in the literature,28,29
condition screens have been developed. The conditions under optimization currently are as
follows: 0.2 M calcium acetate, 20% (w/v) PEG 3350, and 0.1 M Tris HCl pH 6.5 – henceforth
“Condition Set A”. Optimization efforts include varying Condition Set A’s pH from 6.3-6.6 at
intervals of 0.1, and its precipitant (PEG 3350) concentration from 17-22% at intervals of 1%.
Condition Set A’s protein solution concentration, originally reported as 10 mg/mL,28 has been
extrapolated into three separate concentrations: 10 mg/mL, 20 mg/mL, and 30 mg/mL. The final
well volume is 1 mL, and the drop ratio of protein solution to mother liquor is 1:1. These conditions
are simulated in screen format in Figure 29.
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Figure 29: Simulations for apo-BSA crystallization setups. Each rectangle corresponds to a single well that possesses
characteristics of the corresponding PEG and pH row and column respectively. The protein concentrations used for
those respective screens are provided in the tables’ upper-leftmost corner.

Out of the conditions tested in Figure 29, crystals have been observed at a 10 mg/mL protein
concentration where the pH was 6.3 and the PEG 3350 concentrations were 19-22% (Figure 30),
but their lack of three-dimensional morphology resulted in them being unviable for x-ray
diffraction techniques (Figure 31).

Figure 30: A simulated view of tray conditions for apo-BSA crystallization at [BSA] = 10 mg/mL. Each rectangle
corresponds to a single well that possesses characteristics of the corresponding PEG and pH row and column
respectively. Conditions for which crystals developed are marked by an “X”
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Figure 31: Apo-BSA crystals acquired from Crystal Set A. pH was 6.3 for each drop. PEG concentrations for each
drop were as follows: (a) 19%, (b) 20%, (c) 21%, (d) 22%

As seen in Figure 30’s pictures, (a) and (c) contain thin needle-like formations, (b) possesses a
large number of microcrystals, and (d) possesses needle clusters. Each of these crystals lacks the
optimized depth (i.e. number of lattice planes) needed for x-ray diffraction. This could be due to
the PEG 3350 concentration being too low causing the diffusion rate to be insufficient to stimulate
crystal growth to the degree desired. Regardless of the experimental condition, BSA crystallization
is considerably more difficult given its larger molecular weight (~66,463 kDa) and corresponding
complexity to other proteins in this work, so continued condition optimization is required. Much
like Ni-NBP, if better crystals were to form, they would be taken to Argonne National Laboratory
for x-ray diffraction and structure elucidation.
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4.4 Au-BSA Crystallization
Current efforts to crystallize Au-BSA are directed toward condition optimization. All
crystallization occurred at room temperature (~20°C). Guided by success in the literature, 28,29,30
condition screens have been developed. The conditions under optimization currently are as
follows: 22%(w/v) PEG 5000, 0.3 M NH4Cl, and 0.1 M MES pH 6.5 – henceforth “Condition Set
B”.
Optimization efforts include varying Condition Set B’s pH from 6.3-6.6 at intervals of 0.1,
and its precipitant (PEG 5000) concentration from 20-25% at intervals of 1%. Condition Set B’s
protein solution concentration, originally reported as an unspecific range of 40-120 mg/mL,29 has
been extrapolated into five separate concentrations: 40 mg/mL, 60 mg/mL, 80 mg/mL, 100
mg/mL, and 120 mg/mL. 10 equivalents of chloroauric acid (HAuCl4) was added to the Condition
Set B’s protein solution. The final well volume is 1 mL, and the drop ratio of protein solution to
mother liquor is 1:1. These conditions are simulated in screen format in Figure 32.
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Figure 32: Simulations for Au-BSA crystallization setups. Each rectangle corresponds to a single well that possesses
characteristics of the corresponding PEG and pH row and column respectively. The protein concentrations used for
those respective screens are provided in the tables’ upper-leftmost corner, as are the Au equivalents.
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Out of the conditions tested in Figure 32, no crystals have been observed for any of the well
conditions regardless of protein concentration including those of Condition Set B; however,
precipitation has been observed as has a violet coloration in the drop solution (Figure 33).

Figure 33: Representative sample of Au-BSA drop. Note the development of a skin around the drop’s circumference
and the violet precipitate’s nebula-like structure. These characteristics are noted in each well system regardless of
condition change

This color is believed to be caused by the Tris buffer reducing the gold in solution. Regardless, the
existence of precipitate suggests either the protein concentration or salt concentration is too high,
so lower concentrations for both of these variables are potential avenues of future crystallization
attempts. As of yet, a viable crystal has not been developed, though if they were, they would be
taken to Argonne National Laboratory for x-ray diffraction and structure elucidation.
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Chapter 5: De Novo Tetramer
5.1 Background
The de novo tetramer is an attempt to expand comprehension of protein structures by
exploring the characteristics of an artificially-designed α-helical tetramer barrel. This exploration’s
main aim is to rely on the known sequence-to-structure relationships of the α-helical coiled coil31,32
to further knowledge of peptide engineering so as to inform future research efforts in the
determination of potential applications in the fields of synthetic biology or biotechnology.
Additionally, this α-helical tetramer’s interactions with transition metals nickel and iron are also
investigated.
A discussion of protein structure is required to understand this section. Proteins are
composed of amino acids chained together by condensation reactions to form peptide bonds which
cumulatively comprise a chain of amino acids also known as a peptide’s primary sequence, an
example of which is visualized in the synthesis of the tripeptide Glycine-Glycine-Glycine (Figure
34).33

Figure 34: Shown is the binding of three glycine residues together to create a tripeptide. Formation causes the
expulsion of two water molecules in two instances of one hydrogen from an amine group and one hydroxyl from a
carboxylic acid group. In the figure, hydrogens are yellow, carbons are grey, oxygens are red, and nitrogens are blue.
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As more amino acids are chained together, the peptide backbone’s amino hydrogens and carbonyl
oxygens may interact through hydrogen bonding to form α-helices, β-pleated sheets, β-turns, or
Ω-coils, collectively known as secondary structures, of which the former is pertinent to this work.
The use of coiled-coil α-helices is due to a greater degree of comprehension regarding their
sequence-to-structure relationships. This comprehension arrives as a pattern of hydrophilic (P) and
hydrophobic (H) residues typically in a seven-unit heptad repeat (HPPHPPP)n which can also be
denoted as abcdefg and visualized as a helical wheel (Figure 35).34

Figure 35: Helical wheel representation of heptad repeat sequence abcdefg displaced around an α-helix. Residues that
are nearer to the helix interfaces are shaded more darkly

Additionally, α-helices with this heptad repeat demonstrate intramolecular interactions through
sidechains known as knob-into-holes (KIH) packing with other α-helices of the same heptad
repeat.34,35 Combined, KIH packing and the heptad repeat provide a foundation from which these
coiled-coil α-helices can be computationally35,36,[x],37 and rationally designed.38,39
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As this applies to this work, THE DE NOVO TETRAMER’s α-helices are 30 residues long
with a molecular weight 3301.91 g/mol and a theoretical pI of 6.36. It is overall composed of four
α-helices arranged about a central axis to create an inner region of open space which may be used
for metal binding. The de novo tetramer’s primary sequence contains two Cys residues which
when utilized in conjunction with the protein’s tetramer structure results in eight Cys residues
arranged in a metal-binding pocket similar theoretically in functionality to NBP. SC01’s primary
sequence is Ac-GLAAIEQKCEACEKKLEAIEKKLAAIEWKG-CONH2, its helical wheel is
represented in Figure 36, and 3D models of the protein’s tertiary structure and Cys pocket spacing
are visualized in Figure 37a and Figure 37b respectively.

Figure 36: De novo tetramer helical wheel
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Figure 37: (a) CS-01’s four α-helices arranged so their individual Cys residues form a central pocket for potential
transition metal binding. (b) The Cys binding pocket with atomic distances in Å. Note the equally-spaced squares of
edge length 3.9 Å and 2.4 Å respectively

5.2 Synthesis and Purification Procedure
Peptide synthesis was done by standard Fmoc SPPS protocols on a CEM LibertyBLUE
microwave-assisted automated peptide synthesizer (CEM Corporation, Buckingham, UK).
Peptides were synthesized on a Rink amide ChemMatrix resin (PCAS Biomatrix, Quebec, Canada)
by taking advantage of HBTU activation. After automated synthesis, peptide acetylation using
acetic anhydride and pyridine in DMF was performed. The crude peptide was then cleaved from
the resin by treatment with a 95:2.5:2.5 mix of trifluoroacetic acid:water:triisopropylsilane for 2
hours at room temperature. The cleavage mixture was then dripped into ten times the volume of
0°C diethyl ether, and the precipitate that formed was isolated by centrifugation. The solid was
dissolved in a 1:1 mix of water and acetonitrile and freeze-dried to give the crude peptide. This
material was purified using reversed-phase HPLC using a C18 column (10 × 150 mm, Kromatek,
UK) and running a gradient from 20 % to 80 % acetonitrile in water over 30 minutes.
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5.3 Crystallization
De Novo Tetramer
Current efforts to crystallize the de novo tetramer are directed toward condition
optimization. All crystallization occurred at room temperature (~20°C). Guided by success in the
literature,40,41 condition screens have been developed. The conditions under optimization currently
are as follows: 1) 1.26M Ammonium sulfate and 0.1 M Tris pH 8.2-8.7 and 2) 25 mM imidazole
pH 6.9-7.2, PEG 8000 20-25%, and 14.3% ethanol henceforth Condition Set C and Condition Set
D respectively. Optimization efforts include varying the pH of both condition sets by intervals of
0.1, and its precipitant (PEG 8000) concentration, when applicable, at intervals of 1%. The peptide
concentrations tested have been 10 mg/mL and 20 mg/mL for both condition sets. The final well
volume is 1 mL, and the drop ratio of protein solution to mother liquor is 1:1. These conditions are
simulated in screen format in Figure 38.

45

Figure 38: Conditions under optimization for the de novo tetramer in screen format

Out of these screens, a single well from Condition Set D yielded crystals (Figure 39).

Figure 39: A simulated view of tray conditions for de novo crystallization. Each rectangle corresponds to a single
well that possesses characteristics of the corresponding PEG and pH row and column respectively. Conditions where
crystals developed are marked by an “X”
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These crystals are pictured in Figure 40.

Figure 40: De novo tetramer crystals formed from Condition Set D

Note the crystals’ square-like shape, sharp edges, concentric rings indicating 3D structure, and size
relative to more granular precipitate indicating successful crystal formation. As crystals formed,
they are to be taken to Argonne National Laboratory for x-ray diffraction and structure elucidation
later in April.
Chapter 6: Conclusion

6.1 Conclusion
In summary, Crystals were successfully formed for apo-NBP and the de novo tetramer.
The apo-NBP’s crystal was analyzed via crystal diffraction techniques from which data was
extracted so a 3D structure could be made. The de novo tetramer crystal will be exposed to crystal
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diffraction techniques later in April at the Argonne National Laboratory where, if the crystals prove
to be of sufficient quality, a 3D structure may be determined for it also. Further optimization must
take please for Ni-NBP, apo-BSA, and Au-BSA crystal screen conditions. While crystals were
observed for apo-BSA, their lack of 3D structure rendered them unviable for crystal diffraction
efforts. Au-BSA screens, the ample presence of precipitate likely indicates protein concentrations
under optimization are too large and that lowering these concentrations would yield more
quantifiable results. Also, a change in the buffer used for the mother liquor may be required to
prevent gold reduction and the subsequent violet coloration observed from said reduction. As for
Ni-NBP, the lack of crystal formation could have resulted from numerous factors from protein’s
concentration being too low to interference from the nickel in solution, though the complex nature
of protein crystallization still allows for the conditions under consideration to be potentially viable.
It could be that these efforts just require more time to be brought to fruition.
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